title: Does early migraine treatment shorten time to headache peak and reduce its severity?
abstract: OBJECTIVE
  To explore whether early treatment would shorten the duration of headache from headache onset to its peak and reduce headache severity at peak.
  
  
  BACKGROUND
  Prior clinical studies almost exclusively focused on headache relief after dosing. No data are available on whether early intervention affects the duration from headache onset to peak and headache severity at peak.
  
  
  METHODS
  Adult migraineurs were enrolled in this observational study from multi-site headache clinics. Patients recorded their migraine experiences via an electronic diary over 1 month. Patients reported the time and pain severity at onset, dosing, and peak. We used a linear mixed model to evaluate the impact of the timing of treatment and to adjust for covariates and correlation of observations within subjects.
  
  
  RESULTS
  A total of 182 patients reported 970 migraine episodes, 620 of which were treated before headaches progressed to peak. Mean time from headache onset to peak varied from 1.9 hours to 8.9 hours for patients treated within 15 minutes of onset and those who waited for 4 or more hours, respectively. However, early intervention was not associated with reduced headache severity at peak. In multivariate analysis, early treatment, use of triptans, and mild migraine headache in the past 3 months were significantly associated with shorter time from onset to headache peak. A separate model indicated that the timing of medication was not associated with the duration between dosing and headache peak, but use of triptans shortened the time from dosing to headache peak.
  
  
  CONCLUSIONS
  Early treatment and use of triptans may lead to shorter duration from migraine headache onset to its peak but did not alleviate headache severity at peak. This could result in decreased migraine burden by reducing total migraine headache duration.
authors.affiliation: Global Outcomes Research, Global Human Health, Merck & Co., Inc., Whitehouse Station, NJ, USA.
authors.forename: X Henry
authors.initials: XH
authors.lastname: Hu
authors.forename: Daisy
authors.initials: D
authors.lastname: Ng-Mak
authors.forename: Roger
authors.initials: R
authors.lastname: Cady
mesh_terms: D000328:Adult; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy* / Q000503:physiopathology; D015999:Multivariate Analysis; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014363:Tryptamines / Q000008:administration & dosage* / Q000627:therapeutic use*
chemical_list: D014363:Tryptamines